Search

The last three patients: dermatology (Patient Three)

For the third and final reflection in this series (see Part 1 and Part 2), Professor Jonathan Rees recounts his experience of a patient with cancer who was failed by the NHS, and how their inadequate treatment illuminates some issues...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Eye research: where next?

Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...

Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions

The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Retinoblastoma – the challenges of a rare cancer and the role of international partnerships

Introduction: the global challenge The global burden of retinoblastoma (Rb) is one in 15,000-18,000 live births, which equates to 8000 new cases worldwide each year. The global disparities in Rb outcome represent a paradigm of health inequality worldwide [1]. In...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

DR-NET Workshop – information-sharing for strengthening DR programmes

Contributors: Rosie Brennan, Anshul Chauhan, Mona Duggal, John Ellis, Michael Gichangi, Edwin Grayson, Catherine Jamieson, Ankita Kankaria, Oliver Kemp, Hendra Kusuma, Nanda Matthew, Geeta Menon, Habibah Muhiddin, Tunde Peto, Recivall Salongcay, Frank Sandi, Hazel Shillingford-Ricketts, Bernadetha Shilio, Caroline Styles, Sharon...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

The ocular manifestations of COVID-19: an overview of current literature

Although respiratory symptoms are the most frequent manifestation of COVID-19, multi-organ involvement has been demonstrated, including ocular manifestations. The author investigates how the eye can be affected. The SARS-CoV-2 virus responsible for the COVID-19 pandemic has presented a significant public...